{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:36:10Z","timestamp":1773297370538,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jid.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T17:42:03Z","timestamp":1638553323000},"page":"1256-1259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["BRAF Inhibitors in Melanoma Management: When Friends Become Foes"],"prefix":"10.1016","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5205-7218","authenticated-orcid":false,"given":"Gagan","family":"Chhabra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4239-9887","authenticated-orcid":false,"given":"Nihal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2021.11.005_bib1","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.jid.2020.03.972","article-title":"Efficient suppression of NRAS-driven melanoma by co-inhibition of ERK1\/2 and ERK5 MAPK pathways","volume":"140","author":"Adam","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.005_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2217\/mmt-2017-0023","article-title":"Combating NRAS mutant melanoma: from bench to bedside","volume":"4","author":"Echevarr\u00eda-Vargas","year":"2017","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.jid.2021.11.005_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijc.23876","article-title":"Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in\u00a0vitro","volume":"124","author":"Eskandarpour","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.jid.2021.11.005_bib4","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jid.2021.10.007","article-title":"Vemurafenib drives epithelial-to-mesenchymal transition gene expression in BRAF inhibitor-resistant BRAFV600E\/NRASQ61K melanoma enhancing tumor growth and metastasis in a bioluminescent murine mode","volume":"142","author":"Jandova","year":"2022","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2021.11.005_bib5","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","article-title":"Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the\u00a0spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms","volume":"51","author":"Johnson","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jid.2021.11.005_bib6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2017.01.029","article-title":"Potential therapeutic targets of epithelial-mesenchymal transition in melanoma","volume":"391","author":"Pearlman","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.jid.2021.11.005_bib7","article-title":"Epithelial-to-mesenchymal-like transition events in melanoma [e-pub ahead of print]","author":"Pedri","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.jid.2021.11.005_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2021.11.005_bib9","doi-asserted-by":"crossref","first-page":"856","DOI":"10.3389\/fphar.2018.00856","article-title":"MMP-9 as a candidate marker of response to BRAF inhibitors in melanoma patients with BRAFV600E mutation detected in circulating-free DNA","volume":"9","author":"Salemi","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jid.2021.11.005_bib10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cell.2019.01.002","article-title":"Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis","volume":"176","author":"Yin","year":"2019","journal-title":"Cell"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21024854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X21024854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:48:47Z","timestamp":1762206527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X21024854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0022202X21024854"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.005","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF Inhibitors in Melanoma Management: When Friends Become Foes","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2021.10.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}